Loading
Cytosorbents Corp Stock: price and insider trades · United States
3 insiders bought €104k of shares over the last 90 days, the latest filed 16 Sept 2026.
Cytosorbents Corp: what insiders have been doing
Headquartered in Monmouth Junction, Cytosorbents Corp belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 11 filings came from 4 insiders.
Every open-market trade in the period is a purchase: 10 purchases worth €104k, from 4 insiders, and not a single sale. The amount is not disclosed for 3 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €60k from Chan Phillip P., disclosed on 9 September 2026, or 0.44% of market capitalisation. Among those who bought: 2 senior executives, 1 finance chief and 1 chief executive.
Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 11 filings, this issuer sits below that mark. Looking back to 2016, when coverage begins, insiders filed 42 purchases and 10 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 37.1 m USD and net income of -8.2 m USD.
Within a 30-day window, 6 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The clock since the last published purchase (16 September 2026) now reads 31 days. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
94
Thresholds
n/a
Buy Volume
€650,360
42 ops. · all time
Sell Volume
n/a
10 ops. · all time
Who traded when
BuySalePhillip P. Chan4 buys
Alan D. Sobel3 buys
Peter J. Mariani3 buys
Vincent Capponi2 buys
Since the insiders bought
- -52.0%Entry US$6.37 · Close 15 Oct 2026 US$3.06
- -36.5%Entry US$9.54 · Close at T+90 US$6.06
- -65.0%Entry US$59.40 · Close at T+365 US$20.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,040 of 24,148 companies
25.0
score / 100
Value2
Quality48
FCF yld-99%
Earn yld-63%
EV/EBITDA·
ROE·
Gross mgn71%
Net mgn-22%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.09
Analyst consensus
2 analysts3.00/5
US$15.00Target US$47.50(+1437%)US$80.00
Income statement
RevenueUS$37.1M
Gross profitUS$26.5M71% margin
EBITDA-US$4.4M-12% margin
Net income-US$8.2M-48.9% margin
Valuation
P/Book10.3x
Beta1.37
Balance sheet & cash
Market capUS$9.7M
Total debtUS$29.1M
Free Cash Flow-US$12.9M
Debt / Equity1334%
Profitability & ownership
ROE-336.2%
ROA-17.1%
% insiders16.3%
% institutions25.5%
Last declaration on 16 September 2026
Declarations94 total
1,800 shares@ US$6.070.069% mcap8.1% of flowCommon StockSEC:0001104659-26-108247:0
Canonical exit: 13 Dec 2026 (T+90)
273 shares@ US$5.900.010% mcap1.2% of flowCommon StockSEC:0001104659-26-108247:1
Canonical exit: 13 Dec 2026 (T+90)
3,774 shares@ US$6.000.14% mcap3.4% of flowCommon StockSEC:0001104659-26-108326:0
Canonical exit: 14 Dec 2026 (T+90)
1,900 shares@ US$6.120.074% mcap11.4% of flowCommon StockSEC:0001104659-26-108246:0
Canonical exit: 14 Dec 2026 (T+90)
500 shares@ US$6.050.019% mcap3.0% of flowCommon StockSEC:0001104659-26-108246:1
Canonical exit: 14 Dec 2026 (T+90)
100 shares@ US$6.010.0038% mcap0.6% of flowCommon StockSEC:0001104659-26-108246:2
Canonical exit: 14 Dec 2026 (T+90)
200,000 shares@ US$0.350.44% mcap10.4% of flowCommon StockSEC:0001104659-26-106308:0
Canonical exit: 3 Dec 2026 (T+90)
100,000 sharesCommon StockSEC:0001104659-26-074291:0
Canonical exit: 13 Sept 2026 (T+90)
251,136 sharesCommon StockSEC:0001104659-26-074164:0
Canonical exit: 10 Sept 2026 (T+90)
10,333 sharesCommon StockSEC:0001104659-26-074164:1
Canonical exit: 13 Sept 2026 (T+90)
100,000 shares@ US$0.649.6% of flowCommon StockSEC:0001104659-25-114706:0
105,600 shares0Common StockSEC:0001104659-25-075797:0
71,500 shares0Common StockSEC:0001104659-25-075794:0
89,100 shares0Common StockSEC:0001104659-25-075792:0
70,000 shares0Common StockSEC:0001104659-25-075791:0
10,000 shares@ US$1.1312.6% of flowCommon StockSEC:0001104659-25-020516:0
34,168 shares@ US$1.136.4% of flowCommon StockSEC:0001104659-25-017619:0
21,950 shares@ US$1.1326.8% of flowCommon StockSEC:0001104659-25-017618:0
32,625 shares@ US$1.1337.1% of flowCommon StockSEC:0001104659-25-017620:0
12,000 shares@ US$1.1311.2% of flowCommon StockSEC:0001104659-25-017621:0
16,233 shares@ US$1.0036.2% of flowCommon StockSEC:0001104659-25-005355:0
32,625 shares@ US$1.0033.4% of flowCommon StockSEC:0001104659-25-005352:0
15,879 shares@ US$1.0018.1% of flowCommon StockSEC:0001104659-25-005358:0
31,760 shares@ US$1.0026.6% of flowCommon StockSEC:0001104659-25-005356:0
21,950 shares@ US$1.0024.1% of flowCommon StockSEC:0001104659-25-005354:0
25 of 94 declarations
About Cytosorbents Corp
CytoSorbents Corp. is a United States-based medical technology company listed on the NASDAQ under ticker CTSO. The company operates in the blood purification and critical care device space, with a focus on intensive care, cardiac surgery, and extracorporeal adsorption therapies. Its corporate headquarters and main operating facility are in Princeton, New Jersey, while it also maintains facilities in Berlin, Germany. That footprint is important because CytoSorbents has built a meaningful commercial base in Europe while continuing to pursue regulatory and commercial opportunities in North America.
The company’s core commercial product is CytoSorb, a proprietary blood purification device used primarily in intensive care and cardiac surgery settings. CytoSorb is designed to adsorb certain inflammatory mediators and other unwanted substances from the blood, making it relevant in severe inflammatory conditions, sepsis-related care, and complex perioperative use cases. In Europe, CytoSorb has CE-mark approval and remains the principal revenue driver for the company. CytoSorbents also markets VetResQ in the U.S. animal health market, expanding its reach into veterinary critical care.
Read moreShow less
A key part of the investment case is DrugSorb-ATR, an investigational device in the United States and Canada. Built on equivalent polymer technology, it is intended to reduce perioperative bleeding risk in high-risk surgery patients taking blood thinners, especially in urgent cardiac surgery. CytoSorbents has been actively pursuing FDA approval for DrugSorb-ATR and has described it as a potential second growth engine if it reaches commercialization. The company also commercializes the PuriFi hemoperfusion pump in select international markets.
From a market-position standpoint, CytoSorbents is a niche specialist rather than a broad-based medtech platform. Its competitive strengths come from a focused therapeutic angle, clinical evidence supporting use in select applications, and a recognized presence in Europe, where reimbursement and procedure coding have helped adoption. The company’s products address serious, high-acuity medical conditions where speed of intervention matters and treatment options can be limited.
Historically, CytoSorbents was founded in the 2000s and has evolved around its proprietary adsorption technology. Over time, the business has expanded from a Europe-led commercial model into a more global platform spanning Europe, Switzerland, the United Kingdom, the U.S. animal health market, and ongoing North American regulatory efforts. Recent business updates in 2025 and 2026 show modest revenue growth, continued cost discipline, and a stated objective of reaching cash flow breakeven in the second half of 2026. Management has also highlighted ongoing FDA interactions around DrugSorb-ATR, which remains a central catalyst. For investors, CTSO is a specialized, catalyst-driven NASDAQ-listed medtech name in the United States, with upside tied to execution, reimbursement, and regulatory progress.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
